	US 7,566,543 B2
	Prion test
Gerrit Jan Garssen, Driebergen (Netherlands); Jorg Günther Jacobs, Lelystad (Netherlands); Joannes Pieter M. Langeveld, Harderwijk (Netherlands); Marinus Adrianus Smits, Harderwijk (Netherlands); Lucien Johannes M. van Keulen, Oudemirdum (Netherlands); Bram Edward C. Schreuder, Lelystad (Netherlands); and Alexander Bossers, Lelystad (Netherlands)
Assigned to ID-Lelystad, Instituut Voor Dierhouderij en Diergezonheid B.V., Lelystad (Netherlands)
Filed on Oct. 22, 2007, as Appl. No. 11/977,089.
Application 11/977089 is a continuation of application No. 09/913345, granted, now 7,344,842, previously published as PCT/NL00/00079, filed on Feb. 09, 2000.
Claims priority of application No. 99200391 (EP), filed on Feb. 11, 1999.
Prior Publication US 2008/0153117 A1, Jun. 26, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 1/30 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)

U.S. Cl. 435—7.1 [435/40.5; 530/300; 530/350; 424/130.1; 424/139.1; 424/184.1]

11 Claims

1. A method for increasing the discriminating value of a test when testing at least one sample obtained from a mammal for the presence or absence of an aberrant prion protein, the method comprising:

using said at least one sample to prepare a test set and a control set without administration of a denaturation agent;

denaturing protein in said test set with guanidine thiocyanate or one or more chaotropic agents so as to enhance antibody reactivity towards aberrant protein, while antibody reactivity towards a normal form of the protein is reduced or unchanged;

leaving said control set untreated with guanidine thiocyanate or one or more chaotropic agents;

incubating said test set and said control set with anti-PrP^Scantibodies;

probing said test set and said control set for the presence or absence of an aberrant prion protein; and

determining with said anti-PrP^Scantibodies instances of increased antibody reactivity as a function of denaturation in guanidine thiocyanate or one or more chaotropic agents in the test set versus the control set.